Juliet Thompson, Joanna Le Couilliard, Mark Stejbach and Jerome Lande have taken board roles at the pharmaceutical firm.
Pharmaceutical company Indivior has appointed four new non-executive directors to its board.
Juliet Thompson, Joanna Le Couilliard and Mark Stejbach join as independent NEDs, with Jerome Lande, a partner at Indivior shareholder Scopia, joining as a NED.
Thompson is a former investment banker who has spent her career advising pharmaceutical companies. She currently chairs the audit committees of Novacyt and Vectura, and is also a non-executive director of Organox. She will be a member of the audit and nomination and governance committees, and will be appointed to chair the audit committee following the 2021 AGM in May.
Le Couilliard w
For thoughtful journalism, expert insights on corporate governance and an extensive library of reports, guides and tools to help boards and directors navigate the complexities of their roles, subscribe to Board Agenda